Table 1.
General characteristics of the study population.
| N = 1071 | |||
|---|---|---|---|
| Age (mean ± SD) | 47.72 ± 16.22 | ||
| Menopausal status | |||
| Premenopausal | 629 (58.73%) | ||
| Postmenopausal | 442 (41.27%) | ||
| Pathology | |||
| Benign | 778 (72.64%) | ||
| Epithelial tumor | 331 (42.5%) | ||
| Endometrioma | 210 (26.9%) | ||
| Fibroids | 56 (7.2%) | ||
| Other sex cord-stromal tumors | 4 (0.5%) | ||
| Germ cell tumors | 149 (19.2%) | ||
| Fallopian tube lesions | 24 (3.1%) | ||
| Tubo-ovaric abscesses | 4 (0.5%) | ||
| Epithelial borderline | 74 (6.91%) | ||
| Epithelial ovarian cancer (EOC) | 197 (18.39%) | FIGO stage for EOC | |
| Serous carcinoma | 124 (62.94%) | FIGO Stage I | 58 (29.44%) |
| Mucinous carcinoma | 8 (4.06%) | FIGO Stage II | 15 (7.61%) |
| Clear cell carcinoma | 17 (8.63%) | FIGO Stage III | 108 (54.82%) |
| Endometrioid Carcinoma | 33 (16.75%) | FIGO Stage IV | 16 (8.12%) |
| Undifferenciated Carcinoma | 15 (7.61%) | ||
| Metastatic cancer in the ovary | 22 (2.05%) | ||